
Citation: Khalid Hattaf, Noura Yousfi. Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response[J]. Mathematical Biosciences and Engineering, 2020, 17(5): 5326-5340. doi: 10.3934/mbe.2020288
[1] | A. M. Elaiw, Raghad S. Alsulami, A. D. Hobiny . Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity. Mathematical Biosciences and Engineering, 2023, 20(2): 3873-3917. doi: 10.3934/mbe.2023182 |
[2] | A. D. Al Agha, A. M. Elaiw . Global dynamics of SARS-CoV-2/malaria model with antibody immune response. Mathematical Biosciences and Engineering, 2022, 19(8): 8380-8410. doi: 10.3934/mbe.2022390 |
[3] | Matthew Hayden, Bryce Morrow, Wesley Yang, Jin Wang . Quantifying the role of airborne transmission in the spread of COVID-19. Mathematical Biosciences and Engineering, 2023, 20(1): 587-612. doi: 10.3934/mbe.2023027 |
[4] | Sarafa A. Iyaniwura, Rabiu Musa, Jude D. Kong . A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20(3): 5379-5412. doi: 10.3934/mbe.2023249 |
[5] | Wenhan Guo, Yixin Xie, Alan E Lopez-Hernandez, Shengjie Sun, Lin Li . Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2. Mathematical Biosciences and Engineering, 2021, 18(3): 2372-2383. doi: 10.3934/mbe.2021120 |
[6] | Tahir Khan, Roman Ullah, Gul Zaman, Jehad Alzabut . A mathematical model for the dynamics of SARS-CoV-2 virus using the Caputo-Fabrizio operator. Mathematical Biosciences and Engineering, 2021, 18(5): 6095-6116. doi: 10.3934/mbe.2021305 |
[7] | Yangyang Yu, Yuan Liu, Shi Zhao, Daihai He . A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. Mathematical Biosciences and Engineering, 2022, 19(10): 10361-10373. doi: 10.3934/mbe.2022485 |
[8] | Chentong Li, Jinhu Xu, Jiawei Liu, Yicang Zhou . The within-host viral kinetics of SARS-CoV-2. Mathematical Biosciences and Engineering, 2020, 17(4): 2853-2861. doi: 10.3934/mbe.2020159 |
[9] | David Moreno Martos, Benjamin J. Parcell, Raluca Eftimie . Modelling the transmission of infectious diseases inside hospital bays: implications for COVID-19. Mathematical Biosciences and Engineering, 2020, 17(6): 8084-8104. doi: 10.3934/mbe.2020410 |
[10] | Somayeh Fouladi, Mohammad Kohandel, Brydon Eastman . A comparison and calibration of integer and fractional-order models of COVID-19 with stratified public response. Mathematical Biosciences and Engineering, 2022, 19(12): 12792-12813. doi: 10.3934/mbe.2022597 |
Coronavirus disease 2019 (COVID-19) is a fatal emerging illness caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Since the first case appeared in Wuhan of China at the end of 2019, the disease has spread quickly from country to country, provoking enormous economic damage and lot of deaths worldwide. According to the World Health Organization (WHO) report of 7 June 2020 [2], SARS-CoV-2 infected 6799713 people worldwide and caused 397388 deaths.
Recently, several mathematical models have been proposed and developed to understand the dynamics of SARS-CoV-2. However, most of these models described the propagation of the virus in human population. Therefore, the main objective of this study is to develop a within-host model that describes the interactions between SARS-CoV-2, host pulmonary epithelial cells and cytotoxic T lymphocyte (CTL) cells. This model is governed by the following nonlinear system:
{dUdt=λ−dUU−β1UV1+q1C−β2UI1+q2C,dIdt=β1UV1+q1C+β2UI1+q2C−dII−pIC,dVdt=kI−dVV,dCdt=σIC−dCC, | (1.1) |
where U(t), I(t), V(t) and C(t) respectively indicate the concentration of uninfected pulmonary epithelial cells, infected pulmonary epithelial cells, free virus particles of SARS-CoV-2 and CTL cells at time t. Uninfected pulmonary epithelial cells are generated at a constant rate λ, die at rate dUU and become infected either by free virus particles at rate β1UV or by direct contact with infected pulmonary epithelial cells at rate β2UI. Both modes of infection are inhibited by nonlytic immune response at rates 1+q1C and 1+q2C, respectively. Infected pulmonary epithelial cells die at rate dII and are killed by lytic immune response at rate pIC. The biological meanings of the remaining parameters k, dV, σ and dC are respectively the production rate of virus from infected pulmonary epithelial cells, the clearance rate of virus, the immune responsiveness rate, and the death rate of CTL cells. The schematic illustration of model component interactions is given in Figure 1.
In absence of immune response, model (1.1) is reduced to
{dUdt=λ−dUU−β1UV−β2UI,dIdt=β1UV+β2UI−dII,dVdt=kI−dVV, | (1.2) |
which is a special case of the model presented in [3]. Additionally, system (1.2) covers the within-host model used by Li et al. in [4] in order to estimate the parameters of SARS-CoV-2, it suffices to take β2=0 and λ=dUU(0), where U(0) is the number of uninfected epithelial cells without virus.
In presence of immune response, model (1.1) includes the following models:
● Model of Nowak and Bangham [5], when both cell-to-cell mode and nonlytic immune response are ignored, i.e., β2=0 and q1=0.
● Model of Dhar et al. [6], when the classical virus-to-cell mode is only considered.
The rest of this paper is organized in the following manner. In the next section, we establish some preliminary results about the well-posedness of the model, the existence of feasible biological equilibria and the uniform persistence of infection. In Section 3, we analyze the local and global asymptotic stability of equilibria by means of characteristic equation and Lyapunov functionals. Based on morphometric lungs data and virus environmental stability, the parameters estimation of the model is presented in Section 4. It is followed by numerical simulations in Section 5 to illustrate the obtained analytical results. The last section is devoted to the mathematical and biological conclusions drawn from this study.
In this section, we determine some preliminary results such as the nonnegativity and boundedness of solutions in order to prove that our model (1.1) is biologically well-posed. Additionally, we establish the threshold parameters for the existence of feasible biological equilibria and we also discuss the uniform persistence of the proposed model.
Theorem 2.1. All solutions of model (1.1) with initial conditions in R4+ are nonnegative and bounded.
Proof. We have
dUdt|U=0=λ>0,dIdt|I=0=β1UV1+q1C≥0 for all U,V,C≥0,dVdt|V=0=kI≥0 for all I≥0,dCdt|C=0=0. |
This proves that R4+ is positively invariant with regard to (1.1). Next, we establish the boundedness of solutions by considering the following function
X(t)=U(t)+I(t)+dI2kV(t)+pσC(t). |
Hence,
dXdt=λ−dUU(t)−dI2I(t)−dIdV2kV(t)−pdCσC(t)≤λ−dX(t), |
where d=min{dU,dI2,dV,dC}. Thus,
lim supt→∞X(t)≤λd. |
Then U(t), I(t), V(t) and C(t) are bounded.
Let U0=λdU. Obviously, the point P0(U0,0,0,0) is the unique infection-free equilibrium (1.1). Then we define the first threshold parameter which represents the basic reproduction number of model (1.1) as follows:
R0=λ(kβ1+dVβ2)dUdIdV=R01+R02, | (2.1) |
where R01=λkβ1dUdIdV is the basic reproduction number of the classical virus-to-cell mode, while R02=λβ1dUdI represents the basic reproduction number of the direct cell-to-cell mode.
In absence of immune response and R0>1, model (1.1) has another biological equilibrium called the infection equilibrium without cellular immunity labeled by P1(U1,I1,V1,0), where
U1=λdUR0, I1=λ(R0−1)dIR0, V1=kλ(R0−1)dIdVR0. |
In presence of immune response, the remaining biological equilibrium of (1.1) satisfies the following equations:
I=dCσ, V=kdCσdV, C= σ(λ−dUU)−dIdCpdC and |
kβ1UdV(1+q1C)+β2U1+q2C=dI+pC. |
Since C≥0, we have U≤λdU−dIdCσdU. This indicates that there is no biological equilibrium when U>λdU−dIdCσdU or λdU−dIdCσdU≤0. Let Y be a function defined on the closed interval [0,λdU−dIdCσdU] as follows
Y(U)=kβ1UdV(1+q1Z(U))+β2U1+q2Z(U)−dI−pZ(U), |
where Z(U)=σ(λ−dUU)−dIdCpdC. We have Y(0)=−σλdC<0 and
Y′(U)=kβ1(1+q1Z(U)−q1UZ′(U))dV(1+q1Z(U))2+β2(1+q2Z(U)−q2UZ′(U))(1+q2Z(U))2−pZ′(U). |
Since Z′(U)=−σdUpdC<0, we have Y′(U)>0.
When the immune response has not been established, we have from the last equation of model (1.1) that σI1−dC≤0. Then we define the second threshold parameter which denotes the reproduction number for cellular immunity as follows
RC1=σI1dC. | (2.2) |
The biological meaning of this number is given in [7]. When RC1<1, we have I1<dCσ, U1>λdU−dIdCσdU and Y(λdU−dIdCσdU)<kβ1U1dV+β2U1−dI=0. Then there is no equilibrium when RC1<1.
When RC1>1, I1>dCσ, U1<λdU−dIdCσdU and Y(λdU−dIdCσdU)>0.
Therefore, model (1.1) has a unique infection equilibrium with cellular immunity P2(U2,I2,V2,C2), where U2∈(0,λdU−dIdCσdU), I2=dCσ, V2=kdCσdV and C2=σ(λ−dUU2)−dIdCpdC.
By applying Theorem 4.6 in [8], we can easily obtain the following result.
Theorem 2.2. If R0>1, then model (1.1) is uniformly persistent, i.e., there exists a positive constant ε, independent of initial conditions, such that
lim inft→+∞U(t)≥ε,lim inft→+∞I(t)≥ε,lim inft→+∞V(t)≥ε,lim inft→+∞C(t)≥ε. |
This section focuses on the stability analysis of the three equilibria P0, P1 and P2. The local stability is established by analyzing the characteristic equation. Whereas, the global stability is obtained by constructing favorable Lyapunov functionals.
Theorem 3.1. The infection-free equilibrium P0 is globally asymptotically stable if R0≤1 and unstable if R0>1.
Proof. Consider the following Lyapunov functional
L0(U,I,V,C)=U0Ψ(UU0)+I+β1U0dVV+pσC, |
where Ψ(x)=x−1−lnx, for x>0. It is obvious that Ψ(x)≥0 for all x>0, and Ψ(x)=0 if and only if x=1. Thus, L0(U,I,V,C)>0 for all U,I,V,C>0 and L0(U0,0,0,0)=0. Further, we have
dL0dt=−dUU(U−U0)2+dII(kβ1U0dIdV+β2U0dI(1+q2C)−1)−q1β1U01+q1CVC−pdCσC≤−dUU(U−U0)2+dII(R0−1)−pdCσC. |
If R0≤1, then dL0dt≤0 with equality if and only if U=U0, I=0, V=0 and C=0. By applying LaSalle's invariance principle [9], we deduce that P0 is globally asymptotically stable when R0≤1.
If R0>1, then the characteristic equation of model (1.1) at P0 is given by
(dU+ξ)(dC+ξ)f0(ξ)=0, | (3.1) |
where
f0(ξ)=ξ2+(dI+dV−β2U0)ξ+dIdV(1−R0). |
We have limξ→+∞f0(ξ)=+∞ and f0(0)=dIdV(1−R0)<0 if R0>1. Thus, the characteristic equation (3.1) has at least one positive eigenvalue when R0>1. Then P0 is unstable if R0>1.
Next, we analyze the asymptotic stability of the two infection equilibria P1 and P2 by assuming that R0>1 and the following hypothesis
q1(C−Ci)(1+q1C1+q1Ci−VVi)≤0,q2(C−Ci)(1+q2C1+q2Ci−IIi)≤0,(H) |
where Ii, Vi and Ci are infected pulmonary epithelial cell, virus and CTL cell components of the infection equilibrium Pi for i=1,2.
Theorem 3.2. Suppose that (H) holds for P1. Then the infection equilibrium without cellular immunity P1 is globally asymptotically stable if RC1≤1<R0 and unstable if RC1>1.
Proof. Consider the following Lyapunov functional
L1(U,I,V,C)=U1Ψ(UU1)+I1Ψ(II1)+β1U1V1kI1V1Ψ(VV1)+pσC. |
The function Ψ was used by many authors (see for example [10,11,12]). By a simple computation, we find
dL1dt=(1−U1U)(λ−dUU)+pdCσ(RC1−1)C+β1U1V1(dVV1kI1+V(1+q1C)V1−IV1I1V−UVI1(1+q1C)U1V1I)+β2U1I1(I(1+q2C)I1−U(1+q2C)U1)+II1(β1U1V1−dII1)−β1U1V1kI1dVV+dII1. |
Since λ=dUU1+β1U1V1+β2U1I1=dUU1+dII1 and kI1=dVV1, we have
dL1dt=−dUU(U−U1)2+pdCσ(RC1−1)C+β1U1V1(3−U1U+V(1+q1C)V1−IV1I1V−UVI1(1+q1C)U1V1I−VV1)+β2U1I1(2−U1U+I(1+q2C)I1−U(1+q2C)U1−II1). |
Hence,
dL1dt=−dUU(U−U1)2+pdCσ(RC1−1)C+β1U1V1(−1−VV1+V(1+q1C)V1+(1+q1C))+β2U1I1(−1−II1+I(1+q2C)I1+(1+q2C))+β1U1V1(4−U1U−IV1I1V−UVI1(1+q1C)U1V1I−(1+q1C))+β2U1I1(3−U1U−U(1+q2C)U1−(1+q2C)). |
From (H), we have
−1−VVi+(1+q1Ci)V(1+q1C)Vi+1+q1C1+q1Ci=q1(C−Ci)1+q1C(1+q1C1+q1Ci−VVi)≤0,−1−IIi+(1+q2Ci)I(1+q2C)Ii+1+q2C1+q2Ci=q2(C−Ci)1+q2C(1+q2C1+q2Ci−IIi)≤0. | (3.2) |
Since the arithmetic means (AM) is greater than or equal to the geometric mean (GM), we have
4−U1U−IV1I1V−UVI1(1+q1C)U1V1I−(1+q1C)≤0 |
and
3−U1U−U(1+q2C)U1−(1+q2C)≤0. |
Then if RC1≤1, we have dL1dt≤0 with equality if and only if U=U1, I=I1, V=V1 and C=0. It follows from LaSalle's invariance principle that P1 is globally asymptotically stable when RC1≤1.
It remains to show the instability of P1 when RC1>1. The characteristic equation at this equilibrium is as follows
(σI1−dC−ξ)f1(ξ)=0, | (3.3) |
where
f1(ξ)=|−dU−β1V1−β2I1−ξ−β2U1−β1U1β1V1+β2I1β2U1−dI−ξβ1U10k−dV−ξ|. |
Then ξ1=σI1−dC is a root of the characteristic equation (3.3). Since RC1=σI1dC>1, we get ξ1>0 which implies that the characteristic equation (3.3) has a positive root when RC1>1. Thus, P1 becomes unstable for RC1>1. This completes the proof.
Theorem 3.3. Suppose that (H) holds for P2. Then the infection equilibrium with cellular immunity P2 is globally asymptotically stable if RC1>1.
Proof. Construct a Lyapunov functional as follows
L2(U,I,V,C)=U2Ψ(UU2)+I2Ψ(II2)+β1U2V2(1+q1C2)kI2V2Ψ(VV2)+pσC2Ψ(CC2). |
By using λ=dUU2+β1U2V21+q1C2+β2U2I21+q2C2=dUU2+dII2+pI2C2, I2=dCσ and kI2=dVV2, we easily get
dL2dt=−dUU(U−U2)2+β1U2V21+q1C2(3−U2U+(1+q1C2)V(1+q1C)V2−IV2I2V−(1+q1C2)UVI2(1+q1C)U2V2I−VV2)+β2U2I21+q2C2(2−U2U+(1+q2C2)I(1+q2C)I2−(1+q2C2)U(1+q2C)U2−II2). |
Thus,
dL2dt=−dUU(U−U2)2+β1U2V21+q1C2(−1−VV2+(1+q1C2)V(1+q1C)V2+1+q1C1+q1C2)+β2U2I21+q2C2(−1−II2+(1+q2C2)I(1+q2C)I2+1+q2C1+q2C2)+β1U2V21+q1C2(4−U2U−IV2I2V−(1+q1C2)UVI2(1+q1C)U2V2I−1+q1C1+q1C2)+β2U2I21+q2C2(3−U2U−(1+q2C2)U(1+q2C)U2−1+q2C1+q2C2). |
Since AM is greater than or equal to GM, we have
4−U2U−IV2I2V−(1+q1C2)UVI2(1+q1C)U2V2I−1+q1C1+q1C2≤0,3−U2U−(1+q2C2)U(1+q2C)U2−1+q2C1+q2C2≤0. |
By the above and (3.2), we deduce that dL2dt≤0 if RC1>1. It is obvious to show that dL2dt=0 if and only if U=U2, I=I2, V=V2 and C=C2. Consequently, {P2} is the largest invariant subset of {(U,I,V,C)|dL2dt=0}. From LaSalle's invariance principle, the steady state P2 is globally asymptotically stable if RC1>1.
When we ignore the nonlytic immune response, we have q1=q2=0 and model (1.1) becomes
{dUdt=λ−dUU−β1UV−β2UI,dIdt=β1UV+β2UI−dII−pIC,dVdt=kI−dVV,dCdt=σIC−dCC. | (3.4) |
In this case, (H) holds. By applying Theorems 3.2 and 3.3, we have the following result.
Corollary 3.4. Assume that R0>1.
(ⅰ) If RC1≤1, then P1 of model (3.4) is globally asymptotically stable.
(ⅱ) If RC1>1, then P1 becomes unstable and P2 of model (3.4) is globally asymptotically stable.
According to our above analytical results, model (1.1) has an unique infection-free equilibrium of the form P0(U0,0,0,0) which biologically represents the healthy state of patient without virus. Then U0=λdU is the total number of healthy pulmonary epithelial cells. In six adult human lungs, the mean alveolar number was 480 million with range 274–790 million, and the range of volume lungs was 2062–4744 mL [13]. For eight normal lungs [14,15], the mean lung volume was 4341 mL with range 3500–5950 mL and the mean number of alveolar type II cells was 37±5 billion. Further, the mean lung volume was estimated to be 4340±285 mL in [16]. Based of the these morphometric data, we estimate λdU to be between 5.7757×104 and 1.2×107 cells/mL. However, the death rate of uninfected epithelial cells was estimated by Lee et al. [17] to be 10−3 day−1. Therefore, we get λ between 57.757 and 1.2×104 cells mL−1 day−1.
The median half-life of SARS-CoV-2 in aerosols was estimated to be between 1.1 and 1.2 hours with 95% credible interval [0.64,2.64], it was approximately 5.6 hours on stainless steel and 6.8 hours on plastic [18]. Then we can estimate the clearance rate dV of SARS-CoV-2 to be between 2.4464 and 15.1232 day−1. It is important to note the values for dV used in [4,19] are included in our estimated range. For example, dV=10 day−1 in [19].
Based on the estimations in [4,19,20], we assume that the death rate of infected cells to be between 0.088 and 0.58 day−1. We recall that the burst size is the mean number of virions produced by an infected cell during its lifespan. In the case of SARS-CoV-2, the burst size is unknown and was approximately estimated to be 103 virions [21]. Thus, we obtain k between 88 and 580 virions cell−1 day−1. The estimation of other parameters are summarized in Table 1.
Parameter | Definition | Value | Source |
λ | Epithelial cells | 57.757–1.2×104 cells mL−1 day−1 | Calculated |
production rate | |||
dU | Death rate of uninfected | 10−3 day−1 | [17] |
epithelial cells | |||
β1 | Virus-to-cell infection rate | 0–1 mL virion−1 day−1 | Assumed |
β2 | Cell-to-cell infection rate | 0–1 mL cell−1 day−1 | Assumed |
dI | Death rate of infected | 0.088–0.58 day−1 | Estimated |
epithelial cells | |||
k | Virion production rate per | 88–580 virions cell−1 day−1 | Calculated |
infected epithelial cell | |||
dV | Virus clearance rate | 2.4464–15.1232 day−1 | Estimated |
σ | Activation rate of | 0–1 mL cell−1 day−1 | Assumed |
CTL cells | |||
dC | Death rate of | 0.05–1 mL cell−1 day−1 | [5] |
CTL cells | |||
p | Clearance rate of infection | 0.05–1 mL cell−1 day−1 | [5] |
q1 | Non-lytic strength against | 0–1 mL cell−1 | Assumed |
virus-to-cell infection | |||
q2 | Non-lytic strength against | 0–1 mL cell−1 | Assumed |
cell-to-cell infection |
In this section, we numerically discuss the dynamics of model (1.1) according to different parameter values.
Based on Table 1, we choose λ=500, dU=0.001, β1=1.12×10−7, β2=1.1×10−7, q1=0.3, q2=0.6, dI=0.56, p=0.06, dV=10, dC=0.85 and the other parameters σ and k are considered as free.
Case 1: When we take σ=0.05 and k=88, we have R0=0.9782≤1. It follows from Theorem 3.1 that the infection-free equilibrium P0(5×105,0,0,0) is globally asymptotically stable. This theoretical result is illustrated by Figure 2 which shows the solutions of model (1.1) with different initial values tend to P0.
Case 2: If σ=1.1×10−3 and k=230, then R0=2.3982>1 and RC1=0.6737≤1. Figure 3 displays that the trajectories of model (1.1) with different initial values converge towards the infection equilibrium without cellular immunity P1(2.0850×105,520.5563,1.1973×104,0). This confirms that P1 is globally asymptotically stable and thus illustrates the analytical result obtained in Theorem 3.2.
Case 3: When σ=4.5×10−3 and k=230, we get R0=2.3982>1 and RC1=2.7559>1. In Figure 4, we observe that the trajectories of model (1.1) starting from different initial conditions tend to the infection equilibrium with cellular immunity P2(3.7506×105,188.2088,4.3292×103,1.6977). This validates the global asymptotic stable of P2 given in Theorem 3.3.
From the explicit formula of the basic reproduction number of R0 given in (2.1), we see that R0 is an increasing function with respect to k and it does not depend on σ. Also, the second threshold parameter RC1 is a increasing function with respect to k and σ (see, Figure 5).
In this article, we have proposed a new mathematical model to better describe the dynamics of COVID-19 in human body with virus-to-cell infection, cell-to-cell transmission, lytic and nonlytic immune responses. We have first provided the result regarding the well-posedness of the proposed model in terms of nonnegativity and boundedness of the solutions. Investigating for the biologically feasible equilibria of this SARS-CoV-2 infection model, we have obtained two threshold parameters which completely determine the dynamics of the model. The first threshold parameter called the basic reproduction number labeled by R0 and the second is the reproduction number for cellular immunity denoted by RC1. We have proved in Theorem 2.2 that the proposed model is uniformly persistent when R0>1, which biologically means that the SARS-CoV-2 persists in the host when R0>1. Further, our analytical results suggest that the infection-free equilibrium P0 is globally asymptotically stable whenever R0≤1 (see, Theorem 3.1). This means the complete eradication of SARS-CoV-2 in human lungs. From our numerical results, this eradication of the virus and the extinction of the infection can be done after five days (see, Figure 2). However, P0 becomes unstable when R0>1 and two scenarios arise depending on the value of the reproduction number for cellular immunity RC1. When RC1≤1, the infection equilibrium without cellular immunity P1 is globally asymptotically stable (see, Theorem 3.2). This indicates that the immune response has not been established, which causes persistence of SARS-CoV-2 in human lungs. When RC1>1, P1 becomes unstable and the infection equilibrium with cellular immunity P2 is globally asymptotically stable (see, Theorem 3.3). In this case, the virus is also persisted in the lungs because of the weak response of cellular immunity (see, Figure 4). Furthermore, we have estimated some parameters of the model based on morphometric data and virus environmental stability.
Currently, there is no licensed drug or vaccine against COVID-19. The results of this study establish new within-host properties of SARS-CoV-2 and they can help the biologists and pharmaceutical companies to develop an effective treatment for COVID-19 that makes the patient's basic reproduction number R0 less than or equal to one, which automatically lead to the eradication of SARS-CoV-2 from the patient's lungs. Since R0 is the sum of the basic reproduction numbers for the virus-to-cell and cell-to-cell transmission modes, the last direct mode of transmission should not be ignored in the dynamics of SARS-CoV-2 infection so as not to underestimate the value of the basic reproduction number.
We would like to thank the editor and anonymous reviewers for their constructive comments and suggestions, which have improved the quality of the manuscript.
There is no conflicts of interest.
[1] | A. E. Gorbalenya, S. C. Baker, R. S. Baric, R. J. de Groot, C. Drosten, A. A. Gulyaeva, et al., The species severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat. Microbiol., 5 (2020), 536. |
[2] | WHO, Coronavirus disease 2019 (COVID-19), Situation Report-139, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139. |
[3] | K. Hattaf, N. Yousfi, Qualitative analysis of a generalized virus dynamics model with both modes of transmission and distributed delays, Int. J. Differ. Equations, 2018 (2018), 1-7. |
[4] | C. Li, J. Xu, J. Liu, Y. Zhou, The within-host viral kinetics of SARS-CoV-2, Math. Biosci. Eng., 17 (2020), 2853-2861. |
[5] | M. A. Nowak, C. R. Bangham, Population dynamics of immune responses to persistent viruses, Science, 272 (1996), 74-79. |
[6] | M. Dhar, S. Samaddar, P. Bhattacharya, R. K. Upadhyay, Viral dynamic model with cellular immune response: A case study of HIV-1 infected humanized mice, Physica A, 524 (2019), 1-14. |
[7] | K. Hattaf, Spatiotemporal dynamics of a generalized viral infection model with distributed delays and CTL immune response, Computation, 7 (2019), 1-16. |
[8] | H. R. Thieme, Persistence under relaxed point-dissipativity (with application to an endemic model), SIAM J. Math. Anal., 24 (1993), 407-435. |
[9] | J. P. LaSalle, The Stability of Dynamical Systems, Regional Conference Series in Applied Mathematics, SIAM Philadelphia, 1976. |
[10] | P. Roop-O, W. Chinviriyasit, S. Chinviriyasit, The effect of incidence function in backward bifurcation for malaria model with temporary immunity, Math. Biosci., 265 (2015), 47-64. |
[11] | C. Yang, X. Wang, D. Gao and J. Wang, Impact of awareness programs on Cholera dynamics: Two modeling approaches, Bull. Math. Biol., 79 (2017), 2109-2131. |
[12] | K. Hattaf, Global stability and Hopf bifurcation of a generalized viral infection model with multidelays and humoral immunity, Physica A, 545 (2020), 123689. |
[13] | M. Ochs, J. R. Nyengaard, A. Jung, L. Knudsen, M. Voigt, T. Wahlers, J. Richter, H. G. Gundersen, The number of alveoli in the human lung, Am. J. Respir. Crit. Care Med., 169 (2004), 120-124. |
[14] | P. Gehr, M. Bachofen, E. R. Weibel, The normal human lung: ultrastructure and morphometric estimation of diffusion capacity, Resp. Physiol., 32 (1978), 121-140. |
[15] | J. D. Crapo, B. E. Barry, P. Gehr, M. Bachofen, E. R. Weibel, Cell number and cell characteristics of the normal human lung, Am. Rev. Respir. Dis., 126 (1982), 332-337. |
[16] | E. R. Weibel, What makes a good lung? The morphometric basis of lung function, Swiss Med. Wkly., 139 (2009), 375-386. |
[17] | H. Y. Lee, D. J. Topham, S. Y. Park, J. Hollenbaugh, J. Treanor, T. R Mosmann, et al., Simulation and prediction of the adaptive immune response to influenza A virus infection, J. Virol., 83 (2009), 7151-7165. |
[18] | N. van Doremalen, T. Bushmaker, D. H. Morris, M. G. Holbrook, A. Gamble, B. N. Williamson, et al., Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, N. Engl. J. Med., 382 (2020), 1564-1567. |
[19] | P. Czuppon, F. Débarre, A. Goncalves, O. Tenaillon, A. S. Perelson, J. Guedj, et al., Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the targeted mechanism, MedRxiv, (2020). |
[20] | A. Gonçalves, J. Bertrand, R. Ke, E. Comets, X. de Lamballerie, D. Malvy, et al., Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load, MedRxiv, (2020). |
[21] | Y. M. Bar-On, A. Flamholz, R. Phillips, R. Milo, Science Forum: SARS-CoV-2 (COVID-19) by the numbers, Elife, 9 (2020), e57309. |
1. | Daniel E. Platt, Laxmi Parida, Pierre Zalloua, Lies, Gosh Darn Lies, and not enough good statistics: why epidemic model parameter estimation fails, 2021, 11, 2045-2322, 10.1038/s41598-020-79745-6 | |
2. | Ana P. Lemos-Paião, Cristiana J. Silva, Delfim F.M. Torres, A New Compartmental Epidemiological Model for COVID-19 with a Case Study of Portugal, 2020, 44, 1476945X, 100885, 10.1016/j.ecocom.2020.100885 | |
3. | Chandan Maji, Mayer Humi, Impact of Media-Induced Fear on the Control of COVID-19 Outbreak: A Mathematical Study, 2021, 2021, 1687-9651, 1, 10.1155/2021/2129490 | |
4. | Mouhcine Naim, Yassine Sabbar, Mostafa Zahri, Behzad Ghanbari, Anwar Zeb, Nadia Gul, Salih Djilali, Fouad Lahmidi, The impact of dual time delay and Caputo fractional derivative on the long-run behavior of a viral system with the non-cytolytic immune hypothesis, 2022, 97, 0031-8949, 124002, 10.1088/1402-4896/ac9e7a | |
5. | Ahmed M. Elaiw, Raghad S. Alsulami, Aatef D. Hobiny, Modeling and Stability Analysis of Within-Host IAV/SARS-CoV-2 Coinfection with Antibody Immunity, 2022, 10, 2227-7390, 4382, 10.3390/math10224382 | |
6. | A. M. Elaiw, Raghad S. Alsulami, A. D. Hobiny, Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity, 2022, 20, 1551-0018, 3873, 10.3934/mbe.2023182 | |
7. | A.M. Elaiw, A.J. Alsaedi, A.D. Hobiny, S. Aly, Stability of a delayed SARS-CoV-2 reactivation model with logistic growth and adaptive immune response, 2023, 616, 03784371, 128604, 10.1016/j.physa.2023.128604 | |
8. | Afnan D. Al Agha, Ahmed M. Elaiw, Shaimaa A. Azoz, Esraa Ramadan, Stability analysis of within‐host SARS‐CoV‐2/HIV coinfection model, 2022, 45, 0170-4214, 11403, 10.1002/mma.8457 | |
9. | Ahmed M. Elaiw, Raghad S. Alsulami, Aatef D. Hobiny, Dynamic Behaviors of a COVID-19 and Influenza Co-Infection Model with Time Delays and Humoral Immunity, 2023, 12, 2075-1680, 151, 10.3390/axioms12020151 | |
10. | N. H. AlShamrani, Stability of an HTLV-HIV coinfection model with multiple delays and CTL-mediated immunity, 2021, 2021, 1687-1847, 10.1186/s13662-021-03416-7 | |
11. | Mingjian Wang, Yuhan Hu, Libing Wu, Dynamic analysis of a SIQR epidemic model considering the interaction of environmental differences, 2022, 68, 1598-5865, 2533, 10.1007/s12190-021-01628-4 | |
12. | Ahmed M. Elaiw, Abdulsalam S. Shflot, Aatef D. Hobiny, Global Stability of Delayed SARS-CoV-2 and HTLV-I Coinfection Models within a Host, 2022, 10, 2227-7390, 4756, 10.3390/math10244756 | |
13. | Ahmed M. Elaiw, Abdullah J. Alsaedi, Afnan Diyab Al Agha, Aatef D. Hobiny, Global Stability of a Humoral Immunity COVID-19 Model with Logistic Growth and Delays, 2022, 10, 2227-7390, 1857, 10.3390/math10111857 | |
14. | A.M. Elaiw, A.J. Alsaedi, A.D. Hobiny, Global stability of a delayed SARS-CoV-2 reactivation model with logistic growth, antibody immunity and general incidence rate, 2022, 61, 11100168, 12475, 10.1016/j.aej.2022.05.034 | |
15. | Behzad Ghanbari, On fractional approaches to the dynamics of a SARS-CoV-2 infection model including singular and non-singular kernels, 2021, 28, 22113797, 104600, 10.1016/j.rinp.2021.104600 | |
16. | Musadaq A. Hadi, Zainab M. Amean, New strategy to control covid-19 pandemic using lead/lag compensator, 2021, 68, 17468094, 102669, 10.1016/j.bspc.2021.102669 | |
17. | Wen-Yang Li, Daqing Wang, Yuhao Guo, Hong Huang, Hongwen Zhao, Jian Kang, Wei Wang, Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19, 2022, 22, 1471-2334, 10.1186/s12879-022-07338-x | |
18. | A. M. Elaiw, A. S. Shflot, A. D. Hobiny, Stability analysis of SARS-CoV-2/HTLV-I coinfection dynamics model, 2022, 8, 2473-6988, 6136, 10.3934/math.2023310 | |
19. | Ahmed M. Elaiw, Abdulsalam S. Shflot, Aatef D. Hobiny, Shaban A. Aly, Global Dynamics of an HTLV-I and SARS-CoV-2 Co-Infection Model with Diffusion, 2023, 11, 2227-7390, 688, 10.3390/math11030688 | |
20. | Ron Sender, Yinon M. Bar-On, Shmuel Gleizer, Biana Bernshtein, Avi Flamholz, Rob Phillips, Ron Milo, The total number and mass of SARS-CoV-2 virions, 2021, 118, 0027-8424, 10.1073/pnas.2024815118 | |
21. | Zain Ul Abadin Zafar, Nigar Ali, Mustafa Inc, Zahir Shah, Samina Younas, Mathematical modeling of corona virus (COVID-19) and stability analysis, 2022, 1025-5842, 1, 10.1080/10255842.2022.2109020 | |
22. | Rojhun O. Macalinao, Jcob C. Malaguit, Destiny S. Lutero, Agent-Based Modeling of COVID-19 Transmission in Philippine Classrooms, 2022, 8, 2297-4687, 10.3389/fams.2022.886082 | |
23. | Amar Nath Chatterjee, Fahad Al Basir, Dibyendu Biswas, Teklebirhan Abraha, Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy, 2022, 10, 2076-393X, 1846, 10.3390/vaccines10111846 | |
24. | A.M. Elaiw, A.D. Al Agha, Global dynamics of SARS-CoV-2/cancer model with immune responses, 2021, 408, 00963003, 126364, 10.1016/j.amc.2021.126364 | |
25. | T. S. Faniran, E. A. Bakare, A. O. Falade, Ali R. Ashrafi, The COVID-19 Model with Partially Recovered Carriers, 2021, 2021, 1687-0042, 1, 10.1155/2021/6406274 | |
26. | A. M. Elaiw, A. D. Al Agha, M. A. Alshaikh, Global stability of a within-host SARS-CoV-2/cancer model with immunity and diffusion, 2022, 15, 1793-5245, 10.1142/S1793524521500935 | |
27. | Ahmed. M. Elaiw, Abdullah J. Alsaedi, Aatef. D. Hobiny, Shaban. A. Aly, Global Properties of a Diffusive SARS-CoV-2 Infection Model with Antibody and Cytotoxic T-Lymphocyte Immune Responses, 2022, 11, 2227-7390, 190, 10.3390/math11010190 | |
28. | Thalia Rodriguez, Hana M. Dobrovolny, Estimation of viral kinetics model parameters in young and aged SARS-CoV-2 infected macaques, 2021, 8, 2054-5703, 10.1098/rsos.202345 | |
29. | Taye Samuel Faniran, Aatif Ali, Nawal E. Al-Hazmi, Joshua Kiddy K. Asamoah, Taher A. Nofal, Matthew O. Adewole, Dan Selişteanu, New Variant of SARS-CoV-2 Dynamics with Imperfect Vaccine, 2022, 2022, 1099-0526, 1, 10.1155/2022/1062180 | |
30. | Khalid Hattaf, Ahmed A. Mohsen, Jamal Harraq, Naceur Achtaich, Modeling the dynamics of COVID-19 with carrier effect and environmental contamination, 2021, 12, 1793-9623, 2150048, 10.1142/S1793962321500483 | |
31. | Khalid Hattaf, Mly Ismail El Karimi, Ahmed A. Mohsen, Zakaria Hajhouji, Majda El Younoussi, Noura Yousfi, Mathematical Modeling and Analysis of the Dynamics of RNA Viruses in Presence of Immunity and Treatment: A Case Study of SARS-CoV-2, 2023, 11, 2076-393X, 201, 10.3390/vaccines11020201 | |
32. | Musyoka Kinyili, Justin B Munyakazi, Abdulaziz YA Mukhtar, Mathematical modeling and impact analysis of the use of COVID Alert SA app, 2021, 9, 2327-8994, 106, 10.3934/publichealth.2022009 | |
33. | A. Sa’adah, D. A. Kamil, G. E. Setyowisnu, 2022, 2501, 0094-243X, 020004, 10.1063/5.0091002 | |
34. | Till D. Frank, SARS-Coronavirus-2 Nonlinear Dynamics in Patients: Three-Dimensional State and Amplitude Space Descriptions, 2021, 90, 0031-9015, 073802, 10.7566/JPSJ.90.073802 | |
35. | T D Frank, SARS-coronavirus-2 infections: biological instabilities characterized by order parameters, 2022, 19, 1478-3967, 036001, 10.1088/1478-3975/ac5155 | |
36. | P. M. Honoré, S. Blackman, E. Perriens, 2023, Chapter 32, 978-3-031-23004-2, 441, 10.1007/978-3-031-23005-9_32 | |
37. | Yafei Zhao, Hui Wu, Hua Cheng, Jie Lou, Model selection and identifiability analysis of HIV and SARS-CoV-2 co-infection model with drug therapy, 2023, 126, 10075704, 107501, 10.1016/j.cnsns.2023.107501 | |
38. | M. I. El Karimi, K. Hattaf, N. Yousfi, Spatiotemporal dynamics of RNA viruses in the presence of immunity and treatment: case of SARS-CoV-2, 2024, 11, 23129794, 518, 10.23939/mmc2024.02.518 | |
39. | L Cuesta-Herrera, F Córdova-Lepe, L Pastenes, A D Arencibia, Y Baldera-Moreno, H A Torres-Mantilla, A mathematical model and simulation scenarios for T and B cells immune response to severe acute respiratory syndrome-coronavirus-2, 2023, 2516, 1742-6588, 012007, 10.1088/1742-6596/2516/1/012007 | |
40. | Puji Andayani, Lisa Risfana Sari, Ngatini Ngatini, 2024, 3083, 0094-243X, 040002, 10.1063/5.0224912 | |
41. | Meng Wang, Yafei Zhao, Chen Zhang, Jie Lou, THE WITHIN-HOST VIRAL KINETICS OF SARS-COV-2, 2023, 13, 2156-907X, 2121, 10.11948/20220389 | |
42. | QING LAN, HUI WU, JIE LOU, JIANQUAN LI, MATHEMATICAL MODELING OF INFECTION MECHANISM BETWEEN MILD AND SEVERE COVID-19 PATIENTS, 2023, 31, 0218-3390, 963, 10.1142/S021833902350033X | |
43. | Ahmed M. Elaiw, Amani S. Alsulami, Aatef D. Hobiny, Global properties of delayed models for SARS-CoV-2 infection mediated by ACE2 receptor with humoral immunity, 2024, 9, 2473-6988, 1046, 10.3934/math.2024052 | |
44. | Yuhao Shou, Jie Lou, STUDIES ON THE INTERACTION MECHANISM BETWEEN THE MRNA VACCINE AGAINST SARS-COV-2 AND THE IMMUNE SYSTEM, 2024, 14, 2156-907X, 2283, 10.11948/20230365 | |
45. | T. D. FRANK, AMPLITUDE EQUATIONS AND ORDER PARAMETERS OF HUMAN SARS-COV-2 INFECTIONS AND IMMUNE REACTIONS: A MODEL-BASED APPROACH, 2024, 27, 0219-5259, 10.1142/S0219525924500012 | |
46. | Omar El Deeb, Antoine Matar, Impact of segregation and integration on infection dynamics: analysis of a Cholera model in a two-population system, 2024, 99, 0031-8949, 105016, 10.1088/1402-4896/ad72b4 | |
47. | Kumama Regassa Cheneke, Abd Allah Hyder, Caputo Fractional Derivative for Analysis of COVID-19 and HIV/AIDS Transmission, 2023, 2023, 1687-0409, 1, 10.1155/2023/6371148 | |
48. | A. El Hassani, B. Bettioui, K. Hattaf, N. Achtaich, Global dynamics of a diffusive SARS-CoV-2 model with antiviral treatment and fractional Laplacian operator, 2024, 11, 23129794, 319, 10.23939/mmc2024.01.319 | |
49. | Hui Wu, Yafei Zhao, Xinjian Xu, Jie Lou, Modeling and analysis of a two-strain immuno-epidemiological model with reinfection, 2025, 81, 14681218, 104188, 10.1016/j.nonrwa.2024.104188 | |
50. | Zhongwei Cao, Chenguang Guo, Zhenfeng Shi, Zhifei Song, Li Zu, Stochastic virus infection model with Ornstein–Uhlenbeck perturbation: Extinction and stationary distribution analysis, 2024, 47, 0170-4214, 7156, 10.1002/mma.9961 | |
51. | Ledyz Cuesta-Herrera, Luis Pastenes, Ariel D. Arencibia, Fernando Córdova-Lepe, Cristhian Montoya, Dynamics of Activation and Regulation of the Immune Response to Attack by Viral Pathogens Using Mathematical Modeling, 2024, 12, 2227-7390, 2681, 10.3390/math12172681 | |
52. | Ibrahim Nali, Attila Dénes, Global Dynamics of a Within-Host Model for Usutu Virus, 2023, 11, 2079-3197, 226, 10.3390/computation11110226 | |
53. | Youssra Hajri, Saida Amine, Dynamics of a within-host HIV/SARS-CoV-2 co-infection model with two intracellular delays, 2025, 232, 03784754, 160, 10.1016/j.matcom.2024.12.027 |
Parameter | Definition | Value | Source |
λ | Epithelial cells | 57.757–1.2×104 cells mL−1 day−1 | Calculated |
production rate | |||
dU | Death rate of uninfected | 10−3 day−1 | [17] |
epithelial cells | |||
β1 | Virus-to-cell infection rate | 0–1 mL virion−1 day−1 | Assumed |
β2 | Cell-to-cell infection rate | 0–1 mL cell−1 day−1 | Assumed |
dI | Death rate of infected | 0.088–0.58 day−1 | Estimated |
epithelial cells | |||
k | Virion production rate per | 88–580 virions cell−1 day−1 | Calculated |
infected epithelial cell | |||
dV | Virus clearance rate | 2.4464–15.1232 day−1 | Estimated |
σ | Activation rate of | 0–1 mL cell−1 day−1 | Assumed |
CTL cells | |||
dC | Death rate of | 0.05–1 mL cell−1 day−1 | [5] |
CTL cells | |||
p | Clearance rate of infection | 0.05–1 mL cell−1 day−1 | [5] |
q1 | Non-lytic strength against | 0–1 mL cell−1 | Assumed |
virus-to-cell infection | |||
q2 | Non-lytic strength against | 0–1 mL cell−1 | Assumed |
cell-to-cell infection |
Parameter | Definition | Value | Source |
λ | Epithelial cells | 57.757–1.2×104 cells mL−1 day−1 | Calculated |
production rate | |||
dU | Death rate of uninfected | 10−3 day−1 | [17] |
epithelial cells | |||
β1 | Virus-to-cell infection rate | 0–1 mL virion−1 day−1 | Assumed |
β2 | Cell-to-cell infection rate | 0–1 mL cell−1 day−1 | Assumed |
dI | Death rate of infected | 0.088–0.58 day−1 | Estimated |
epithelial cells | |||
k | Virion production rate per | 88–580 virions cell−1 day−1 | Calculated |
infected epithelial cell | |||
dV | Virus clearance rate | 2.4464–15.1232 day−1 | Estimated |
σ | Activation rate of | 0–1 mL cell−1 day−1 | Assumed |
CTL cells | |||
dC | Death rate of | 0.05–1 mL cell−1 day−1 | [5] |
CTL cells | |||
p | Clearance rate of infection | 0.05–1 mL cell−1 day−1 | [5] |
q1 | Non-lytic strength against | 0–1 mL cell−1 | Assumed |
virus-to-cell infection | |||
q2 | Non-lytic strength against | 0–1 mL cell−1 | Assumed |
cell-to-cell infection |